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Background: Nintedanib in combination with docetaxel is approved in the European Union and 
other countries for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) 
of adenocarcinoma histology after first-line chemotherapy, based on the overall survival findings 
of Phase III LUME-Lung 1 study. Change in target lesion size over time as a treatment effect 
was assessed in patients from this study.
Methods: Tumor size was evaluated using predefined tumor measurements. Mixed-effects 
models were used to quantify individual relationships between time from randomiza-
tion and tumor burden, measured as the sum of longest diameter (SLD) of target lesions 
and assessed by an independent review (Response Evaluation Criteria In Solid Tumors 
[RECIST] v1.0). Exploratory analyses were conducted on the overall adenocarcinoma popula-
tion, adenocarcinoma patients with time from start of first-line therapy ,9 months (TSFLT ,9), 
adenocarcinoma patients who had progressive disease as best response to first-line therapy 
(PD-FLT), and in squamous cell carcinoma patients.
Results: Estimated mean baseline SLD was 82.5 mm in the adenocarcinoma (n=658), 88.3 mm 
in the TSFLT ,9 (n=405), 98.1 mm in the PD-FLT (n=117), and 94.3 mm in the squamous 
cell carcinoma (n=555) populations. Treatment with nintedanib/docetaxel showed a significant 
reduction in tumor size over time (P,0.0001) in patients with adenocarcinoma compared with 
placebo/docetaxel, and in patients with squamous cell carcinoma (P=0.0049). Treatment dif-
ference at 6 months was 9.7 mm in the overall adenocarcinoma population, 16.8 mm in the 
TSFLT ,9 population, 19.7 mm in the PD-FLT population, and 6.8 mm in the squamous cell 
carcinoma population. SLD at 2 months post-randomization was identified as a surrogate end-
point for overall survival, in addition to progression-free survival, for all except the PD-FLT 
population.
Conclusion: Treatment with nintedanib/docetaxel significantly decreased tumor burden and 
decelerated tumor size over time compared with placebo/docetaxel in the overall adenocar-
cinoma population, including in patients with the poorest prognosis due to aggressive tumor 
dynamics.
Keywords: adenocarcinoma, non-small-cell lung cancer, sum of longest diameters, surrogate 
OS endpoints, squamous cell carcinoma, tumor burden
Introduction
The ultimate aim of any anticancer treatment is to reduce progressive disease (PD) and 
prolong overall survival (OS) of patients.1,2 Measurement of tumor burden has been 
shown to be associated with clinical outcomes in advanced non-small-cell lung cancer 
(NSCLC);3,4 when measured by the sum of longest diameter (SLD) of target lesions, 
baseline tumor burden is a predictor of survival duration.3,4 Tumor growth rate is an 
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independent prognostic factor for patients with lung cancer.5 
Measuring tumor volume changes (eg, tumor size rate, time 
to tumor size, early tumor shrinkage, SLD at specific time 
points, depth of tumor response/nadir) during treatment of 
different tumor types, and in multiple treatment settings, 
provides a quantitative and dynamic evaluation of tumor 
response that can potentially identify early treatment sensitiv-
ity and has been correlated with survival outcomes.4,6–12
The randomized, double-blind, placebo-controlled, Phase 
III LUME-Lung 1 study (ClinicalTrials.gov NCT00805194; 
1199.13), comparing the triple angiokinase inhibitor ninte-
danib in combination with docetaxel with placebo/docetaxel, 
demonstrated a significant improvement in OS in patients 
with NSCLC of adenocarcinoma histology after failure of 
first-line chemotherapy (median OS: 12.6 vs 10.3 months; 
hazard ratio [HR]: 0.83 [95% CI: 0.70–0.99]; P=0.0359).13 
A correlation between OS benefit from nintedanib treatment 
and the continuous variable “time from start of first-line treat-
ment” (TSFLT) has been observed.13,14 In adenocarcinoma 
patients with TSFLT ,9 months (TSFLT ,9), OS was 
significantly longer in the nintedanib arm than in the placebo 
arm, with a 3.0-month improvement (median OS 10.9 vs 7.9 
months; HR: 0.75 [95% CI: 0.60–0.92]; P=0.0073).13
The outcomes of the LUME-Lung 1 study contributed to 
the approval of nintedanib in the European Union and other 
countries for the treatment of patients with locally advanced, 
metastatic, or locally recurrent NSCLC of adenocarcinoma 
histology after first-line chemotherapy.15
In the LUME-Lung 1 study, predefined sensitivity analy-
ses of OS used the prognostic factor of baseline SLD of target 
lesions as an adjustment for baseline tumor burden. When the 
model was adjusted for the baseline SLD, OS remained sig-
nificantly improved with nintedanib/docetaxel in the overall 
adenocarcinoma population and in adenocarcinoma patients 
with TSFLT ,9, and was significant even in all patients. In 
patients with squamous cell carcinoma, there was no differ-
ence in OS (HR: 1.01 [95% CI: 0.85–1.21]; P=0.8907) in 
the primary analysis; however, adjustment for SLD resulted 
in a notable decrease in the HR to 0.92 (95% CI: 0.77–1.10; 
P=0.365). Overall, a greater tumor burden was associated 
with a greater treatment effect in the nintedanib arm.13,16
These observations suggest that tumor characteristics, 
including tumor burden and the dynamics of PD, may have 
predictive potential for nintedanib therapy.17 The current 
investigation extends the analyses of tumor burden. We 
explored the impact of tumor size over time, including the 
identification of surrogate endpoints of survival, as well as 
the time to occurrence of new lesions as a treatment effect 
in patients from the Phase III LUME-Lung 1 study, with a 
specific focus on patients with a poorer prognosis due to 
more aggressive tumors.
Methods
study design and assessments
Details of the LUME-Lung 1 study design and assessments 
have been reported previously13 and are briefly summarized 
below. Patients in the randomized, double-blind, placebo-
controlled, Phase III LUME-Lung 1 study received standard 
intravenous docetaxel (75 mg/m2) on Day 1 and nintedanib 
(200 mg twice daily; nintedanib arm) or matching placebo 
(placebo arm) on Days 2–21, until PD or non-tolerability.13 
Target lesions were assessed by central independent review 
using modified Response Evaluation Criteria In Solid Tumors 
(RECIST) v1.0 at baseline and every 6 weeks after the first 
administration of docetaxel.
All patients provided written informed consent, and the 
study protocol was approved by independent ethics commit-
tees or institutional review boards at each center (Table S1). 
Here, we specifically report exploratory analyses for the over-
all adenocarcinoma population, the population of patients 
with adenocarcinoma and TSFLT ,9, and adenocarcinoma 
patients with PD as their best response to first-line therapy 
(PD-FLT), as well as the population with squamous cell 
carcinoma.
Efficacy outcomes for this study have been previously 
reported.13,18 Treatment with nintedanib/docetaxel signifi-
cantly improved efficacy outcomes in the analyzed adeno-
carcinoma populations (Table S2).
assessment of tumor size
Tumor size was evaluated using all available tumor measure-
ments from patients who had at least two evaluable assess-
ments. Tumor burden was measured as the SLD of target 
lesions, assessed by an independent central review (RECIST 
v1.0) preferentially, although data from investigator assess-
ment (if available) were used for patients without two evalu-
able central independent review measurements.
new lesions
The time to occurrence of new lesions, as recorded by 
RECIST v1.0, was analyzed using a Cox model, Kaplan–
Meier curves, and a log-rank test, similar to the primary 
analysis. Two exploratory sensitivity analyses were carried 
out: first, patients were recorded as being censored using 
the OS results (time to new lesion) and, second, death 
was counted as an event and patients could have either an 
event or be censored using the OS results (new lesion-free 
survival).
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surrogate endpoints for Os
Variables proposed in literature related to tumor size over 
time were evaluated for their predictive value for OS. 
These variables, together with baseline characteristics, were 
included in the stepwise algorithm to determine surrogate 
endpoints for OS, while additionally adjusting for important 
prognostic baseline variables. Baseline characteristics were 
investigated for being predictive for OS. The baseline char-
acteristics included the trial’s stratification factors (Eastern 
Cooperative Oncology Group performance status [0 vs 1], 
prior receipt of bevacizumab [yes vs no], presence of brain 
metastases at baseline [yes vs no]), as well as other charac-
teristics that were predefined in the protocol (sex [female 
vs male], age [,65 vs $65 years], geographic region, race 
category [Asian vs non-Asian], smoking status [current 
smoker vs ex-smoker/never smoked], use of bisphosphonates 
at baseline [yes vs no], best response to first-line therapy 
[complete response/partial response/stable disease vs PD], 
number of metastatic organs [#2 vs .2], adrenal metastases 
[yes vs no], liver metastases [yes vs no], and lactate dehy-
drogenase at baseline [.1 vs #1 upper limit of normal]), 
TSFLT, and SLD of target lesions.
Based on previous clinical methodology and in accor-
dance with RECIST recommendations, these variables 
related to tumor size included the “absolute reduction in 
SLD from baseline to 2 months after randomization”;19,20 
“percentage reduction in SLD from baseline to 2 months after 
randomization”; “SLD at 2 months after randomization”; 
“maximum reduction in SLD compared to baseline”; “maxi-
mum reduction in percentage of SLD compared to baseline”; 
“SLD at nadir (lowest tumor burden after randomization)”;21 
“estimated SLD at baseline”; “time to tumor growth (time to 
nadir)” (Figure S1);6,22,23 “early tumor shrinkage” analyzed 
both as any tumor increase (but without new metastases) 
and as minor shrinkage (both analyses took “new metas-
tases” as the reference population);7,8,10 “time to return to 
baseline SLD”; “observed SLD at baseline”;4 “progression-
free survival (PFS) duration”, including patients who were 
censored in the analysis of PFS; and “PFS flag”, referring to 
the patients who were censored in the analysis of PFS. These 
censored patients were compared with patients who had a 
PFS event (censoring vs event).
statistical analyses and use of surrogate 
endpoints
Mixed-effects models were used to quantify the nonlinear 
individual relationships between time from randomization (t) 
and tumor burden. Several models were evaluated and the 
model that performed best in terms of Akaike Information 
Criterion (a measure of the relative quality of statistical 
models) was used: SLD(t) i=beta1*t+beta2*ln(t+1)+b1i*t+ 
b2i*ln(t+1), where i=1, … , n, n=number of patients, and b1i 
and b2i are random effects. The selected model was flexible, 
allowing for a wide range of differently shaped growth curves 
(U-shaped, J-shaped, N-shaped, and linear-shaped). Cox 
regression and Kaplan–Meier plots were used to evaluate 
and visualize the predictive value of surrogate endpoints. 
A stepwise selection method was used, with inclusion and 
exclusion significance of 0.1.
Results
Patient population
In the LUME-Lung 1 study, there were 658 patients with 
adenocarcinoma histology. Of these, 405 had TSFLT ,9 
and 117 had PD-FLT. In addition, there were 555 patients 
with squamous cell carcinoma. Most patients had metastatic 
cancer at screening; this included 94.2% of the overall 
adenocarcinoma population, 96.8% of the TSFLT ,9 
adenocarcinoma population, 95.7% of the PD-FLT adeno-
carcinoma population, and 86.3% of the squamous cell car-
cinoma population (Table 1). Approximately half the patients 
had one or two metastatic sites at screening (Table S3). In the 
overall adenocarcinoma population, the median duration of 
treatment with nintedanib/docetaxel was 4.2 months (range 
0–41.5) and with placebo/docetaxel was 3.0 months (range 
0–31.7), while in the squamous cell carcinoma population, 
the median duration of treatment with nintedanib/docetaxel 
was 2.8 months (range 0–34.9) and with placebo/docetaxel 
was 2.5 months (range 0–35.6).
Tumor evaluation and baseline tumor slD
A summary of radiologic assessments and baseline SLD 
is shown in Table 2. Most patients had at least one valid 
post-baseline image taken by computed tomography or a 
magnetic resonance imaging scan, with the same method 
used consistently for an individual patient (93.3% of the 
overall adenocarcinoma population, 92.3% of the TSFLT ,9 
adenocarcinoma population, 89.7% of the PD-FLT adeno-
carcinoma population, and 90.5% of the squamous cell 
carcinoma population). The estimated mean baseline SLD 
measurements were larger in the population with the worse 
prognosis (PD-FLT).
Tumor size over time
Estimated tumor size curves for the adenocarcinoma popula-
tions evaluated in this study are shown in Figure 1. Tumor 
size patterns were consistent between treatment arms in all 
adenocarcinoma populations. For adenocarcinoma patients 
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treated with nintedanib/docetaxel, a nonlinear, J-shaped curve 
was observed, indicating a decline in SLD at the beginning of 
treatment. This trend was maintained over time and followed 
by a linear increase in SLD. In contrast, for adenocarcinoma 
patients treated with placebo/docetaxel, a linear increase in 
SLD from baseline over time was observed.
In the overall adenocarcinoma population, disease control 
was achieved in 60.2% of patients in the nintedanib arm and 
44.0% in the placebo arm.13 At baseline, the estimated slope 
of the tumor size curve was –5.80 in the nintedanib arm and 
1.93 in the placebo arm. In the nintedanib arm, the tumor size 
curve nadir was 1.34 and the time when the average SLD 
values returned to baseline was 3–4 months (Figure 1A). Six 
months after randomization, the difference between the two 
treatment arms in the estimated mean SLD measurements 
was 9.7 mm (88.7 mm in the nintedanib arm vs 98.4 mm in 
the placebo arm).
In all adenocarcinoma patient populations, treatment 
with nintedanib/docetaxel produced a significant reduction 
in tumor size over time compared with placebo/docetaxel in 
Table 1 Metastatic sites at screening
Patients with adenocarcinoma histology NSCLC Patients with 
squamous cell 
histology NSCLC
All TSFLT ,9 PD-FLT
Nintedanib 
(n=322)
Placebo 
(n=336)
Nintedanib 
(n=206)
Placebo 
(n=199)
Nintedanib 
(n=53)
Placebo 
(n=64)
Nintedanib 
(n=276)
Placebo
(n=279)
Patients with metastases at screening, n (%) 300 (93.2) 320 (95.2) 197 (95.6) 195 (98.0) 50 (94.3) 62 (96.9) 235 (85.1) 244 (87.5)
Metastatic sites at screening, n (%)
0 22 (6.8) 16 (4.8) 9 (4.4) 4 (2.0) 3 (5.7) 2 (3.1) 41 (14.9) 35 (12.5)
1–2 187 (58.1) 196 (58.3) 116 (56.3) 113 (56.8) 27 (50.9) 34 (53.1) 164 (59.4) 176 (63.1)
.2 113 (35.1) 124 (36.9) 81 (39.3) 82 (41.2) 23 (43.4) 28 (43.8) 71 (25.7) 68 (24.4)
location of metastatic sites at screening, n (%)
lung ipsilateral 163 (50.6) 175 (52.1) 109 (52.9) 103 (51.8) 30 (56.6) 34 (53.1) 105 (38.0) 115 (41.2)
lung contralateral 140 (43.5) 144 (42.9) 87 (42.2) 83 (41.7) 25 (47.2) 29 (45.3) 98 (35.5) 90 (32.3)
Bone 92 (28.6) 100 (29.8) 66 (32.0) 73 (36.7) 18 (34.0) 22 (34.4) 43 (15.6) 48 (17.2)
liver 63 (19.6) 53 (15.8) 45 (21.8) 35 (17.6) 14 (26.4) 13 (20.3) 64 (23.2) 45 (16.1)
adrenal glands 42 (13.0) 56 (16.7) 29 (14.1) 40 (20.1) 8 (15.1) 15 (23.4) 36 (13.0) 45 (16.1)
Brain 26 (8.1) 23 (6.8) 14 (6.8) 10 (5.0) 5 (9.4) 2 (3.1) 6 (2.2) 11 (3.9)
Other 138 (42.9) 156 (46.4) 94 (45.6) 104 (52.3) 26 (49.1) 34 (53.1) 124 (44.9) 129 (46.2)
Abbreviations: NSCLC, non-small-cell lung cancer; PD-FLT, progressive disease as the best response to first-line therapy; TSFLT, time from start of first-line therapy 
,9 months.
Table 2 radiological assessments and baseline slD of target lesions
Patients with adenocarcinoma histology NSCLC Patients with 
squamous cell 
histology NSCLC
All TSFLT ,9 PD-FLT
Nintedanib 
(n=322)
Placebo 
(n=336)
Nintedanib 
(n=206)
Placebo 
(n=199)
Nintedanib 
(n=53)
Placebo 
(n=64)
Nintedanib 
(n=276)
Placebo
(n=279)
Patients with at least 
one valid post-baseline 
image,a n (%)
306 (95.0) 308 (91.7) 196 (95.1) 178 (89.4) 49 (92.5) 56 (87.5) 252 (91.3) 250 (89.6)
number of valid post-
baseline images
1,273 1,125 769 513 230 149 843 737
number of valid post-
baseline images per 
patient, median (range)
3 (1–28) 3 (1–21) 3 (1–21) 2 (1–20) 3 (1–21) 2 (1–13) 2 (1–24) 2 (1–24)
estimated mean 
(range) baseline slDb 
measurements (mm)
82.5 (10.9–391.2) 88.3 (11.2–391.2) 98.1 (11.5–391.2) 94.3 (11.3–313.9)
Notes: aeither cT or Mri scan, with the same method used consistently for an individual patient. bEstimated fixed effects of longitudinal mixed model; the intercept of SLD 
was at Month 0.
Abbreviations: cT, computed tomography; Mri, magnetic resonance imaging; nsclc, non-small-cell lung cancer; PD-FlT, progressive disease as the best response to 
first-line therapy; SLD, sum of longest diameter; TSFLT ,9, time from start of first-line therapy ,9 months.
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Figure 1 Tumor size over time, measured by slD of target lesions, in patients with adenocarcinoma.
Notes: Trajectories are based on the estimated fixed effects of the mixed model. (A) all patients with adenocarcinoma. (B) Patients with adenocarcinoma who progressed 
within 9 months after start of first-line therapy (TSFLT ,9). (C) Patients with adenocarcinoma with PD-FlT.
Abbreviations: PD-FLT, progressive disease as the best response to first-line therapy; SLD, sum of longest diameter; t, time from randomization; TSFLT ,9, time from 
start of first-line therapy ,9 months.
OncoTargets and Therapy 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4578
reck et al
the likelihood ratio test of the treatment effect (P,0.0001 
for the overall adenocarcinoma population). The treat-
ment difference at 6 months was even more pronounced in 
patients with a poor prognosis (P,0.0001 for the TSFLT ,9 
adenocarcinoma population; P=0.0004 for the PD-FLT ade-
nocarcinoma population), as shown in Figure 1B and C.
In all groups, nintedanib/docetaxel produced a significant 
reduction in tumor size over time compared with placebo/
docetaxel. Disease stabilization was greater in patients 
receiving nintedanib than in patients receiving placebo 
(Table S2). Following the same trend, in squamous cell carci-
noma patients, treatment with nintedanib/docetaxel produced 
a significant reduction in tumor size over time compared 
with placebo (P=0.0049; Figure 2). Further estimates for the 
parameterization of the longitudinal model for tumor size are 
reported in Table S4.
Throughout the whole study, there was a sustained differ-
ence in the average SLD of target lesions between the two arms, 
with lower tumor burden in the nintedanib arm (Figure 3).
new lesions
The analysis of the time to occurrence of new lesions favored 
the nintedanib arm and in the second sensitivity analysis was 
significantly longer with nintedanib in the TSFLT ,9 and 
PD-FLT populations (Table 3). The frequency for each site 
was mostly balanced across the two treatment arms. There 
was no specific pattern for the location of new lesions associ-
ated with either treatment arm (Table S5).
surrogate endpoints for Os
Several variables related to tumor size were selected by the 
algorithm as surrogate endpoints for OS (Table 4) in patients 
with a baseline and at least one post-baseline measurement 
(614 patients with adenocarcinoma, 374 patients with 
TSFLT ,9 adenocarcinoma, 105 patients with PD-FLT 
adenocarcinoma, and 502 patients with squamous cell car-
cinoma). The algorithm demonstrated that PFS duration and 
PFS censorship were both predictive for OS in all populations 
evaluated, with the exception of the PD-FLT population, 
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Figure 2 Tumor size over time, measured by slD of target lesions, in patients with squamous cell carcinoma.
Note: Trajectories are based on the estimated fixed effects of the mixed model.
Abbreviations: slD, sum of longest diameter; t, time from randomization.
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Figure 3 Difference between the absolute slD of target lesions (nintedanib arm – 
placebo arm) at different time intervals.
Note: The degree of slD difference shows the degree of response to treatment.
Abbreviations: nsclc, non-small-cell lung cancer; PD-FlT, progressive disease 
as the best response to first-line therapy; SLD, sum of longest diameter; TSFLT, time 
from start of first-line therapy.
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Table 3 Time to occurrence of new lesions
Patients with adenocarcinoma histology NSCLC Patients with 
squamous cell 
histology NSCLC
All TSFLT ,9 PD-FLT
Nintedanib
(n=322)
Placebo
(n=336)
Nintedanib
(n=206)
Placebo
(n=199)
Nintedanib
(n=53)
Placebo
(n=64)
Nintedanib
(n=276)
Placebo
(n=279)
Sensitivity analysis 1a
Patients with event, n (%) 142 (44.1) 154 (45.8) 89 (43.2) 93 (46.7) 19 (35.8) 28 (43.8) 106 (38.4) 111 (39.8)
Time to occurrence of new lesions (months)
Median (months) 11.7 10.9 11.3 9.9 nr 7.3 26.3 18.2
hr (95% ci); P-value 0.88 (0.70–1.11); P=0.2748 0.79 (0.59–1.06); P=0.1181 0.58 (0.31–1.09); P=0.0848 0.88 (0.67–1.14); P=0.3334
Sensitivity analysis 2b
Patients with event, n (%) 285 (88.5) 295 (87.8) 187 (90.8) 182 (91.5) 49 (92.5) 60 (93.8) 259 (93.8) 253 (90.7)
new lesions 142 (44.1) 154 (45.8) 89 (43.2) 93 (46.7) 19 (35.8) 28 (43.8) 106 (38.4) 111 (39.8)
Death 143 (44.4) 141 (42.0) 98 (47.6) 89 (44.7) 30 (56.6) 32 (50.0) 153 (55.4) 142 (50.9)
Time to occurrence of new lesions (months)
Median (months) 6.9 5.6 6.4 4.7 6.0 4.5 5.6 4.6
hr (95% ci); P-value 0.90 (0.76–1.06); P=0.1970 0.77 (0.63–0.95); P=0.0161 0.62 (0.41–0.94); P=0.0232 0.93 (0.78–1.11); P=0.4295
Notes: ain sensitivity analysis 1, patients were recorded as being censored using the Os results (time to new lesion). bin sensitivity analysis 2, death was counted as an event 
and patients could have either an event or be censored using the Os results (new lesion-free survival).
Abbreviations: HR, hazard ratio; NR, not reached; NSCLC, non-small-cell lung cancer; OS, overall survival; PD-FLT, progressive disease as the best response to first-line 
therapy; TsFlT ,9, time from start of first-line therapy ,9 months.
Table 4 surrogate endpoints for Os (tumor size variables)
Population Variable HR (95% CI)a P-valueb
Patients with adenocarcinoma histology NSCLC
all slD of target lesions at 2 months after randomization (cm) 1.005 (1.003–1.006) ,0.0001
eTs (any tumor increase, without new metastases  
vs new metastases)
0.574 (0.422–0.781) 0.0004
eTs (minor tumor shrinkage vs new metastases) 0.711 (0.542–0.934) 0.0143
PFs duration (months) 0.994 (0.992–0.995) ,0.0001
PFS flag (PFS censoring vs PFS event) 0.570 (0.445–0.730) ,0.0001
TsFlT ,9 months slD of target lesions at 2 months after randomization (cm) 1.004 (1.002–1.006) 0.0002
PFs duration (months) 0.994 (0.992–0.995) ,0.0001
PFS flag (PFS censoring vs PFS event) 0.566 (0.416–0.770) 0.0003
PD-FlT slD of target lesions at baseline (cm) 1.007 (1.003–1.010) 0.0004
PFs duration (months) 0.992 (0.989–0.995) ,0.0001
Time to return to baseline slD of target lesions (months) 1.001 (1.000–1.002) 0.0021
Patients with squamous cell histology NSCLC
slD of target lesions at 2 months after randomization (cm) 1.006 (1.004–1.007) ,0.0001
TTg (months) 1.080 (1.015–1.148) 0.0143
PFs duration (months) 0.993 (0.992–0.995) ,0.0001
PFS flag (PFS censoring vs PFS event) 0.474 (0.351–0.639) ,0.0001
Notes: aPlease note that the hrs are not treatment effects. an hr of 1.005 as in line 1 means that an uptake in slD at 2 months of 10 cm increases the risk of death by 
5%. bscore test.
Abbreviations: eTs, early tumor shrinkage; hr, hazard ratio; nsclc, non-small-cell lung cancer; Os, overall survival; PD-FlT, progressive disease as the best response 
to first-line therapy; PFS, progression-free survival; SLD, sum of longest diameter; TSFLT, time from start of first-line therapy to randomization; TTG, time to tumor 
growth.
a finding probably associated with the low numbers of cen-
sored patients in this population (n=14 [12%]). Regarding 
SLD, a smaller SLD at 2 months was predictive for longer 
OS in all the populations evaluated, except for the PD-FLT 
population. Baseline variables that were selected as being 
predictive for OS can be found in Table S6.
Discussion
Our analysis showed that the nintedanib/docetaxel combi-
nation slowed down the tumor dynamics compared with 
placebo/docetaxel, with the largest effect seen in patients 
with the poorest prognosis. Corresponding well with the 
OS findings of LUME-Lung 1, the analyses of data on the 
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impact of the change in target lesion size over time as a 
treatment effect showed that nintedanib/docetaxel signifi-
cantly decreased tumor burden and decelerated tumor size 
compared with placebo/docetaxel in all patients with adeno-
carcinoma and squamous histology. The improvements in 
tumor burden were greatest in the adenocarcinoma PD-FLT 
population, comprising those patients with larger baseline 
tumor burden (poorest prognosis), similar to OS findings.13 
In LUME-Lung 1, in adenocarcinoma patients with PD-FLT, 
the median OS in the nintedanib arm (9.8 months) improved 
by 3.5 months compared with the placebo arm (6.3 months), 
with a 38% reduced risk of new lesions or death. The decrease 
in tumor size was also greatest in this patient population, with 
a treatment difference of 19.7 mm favoring the nintedanib 
arm 6 months after randomization.
Among the adenocarcinoma patient populations ana-
lyzed, baseline tumor burden, as measured by the SLD 
of target lesions or by the number of metastatic sites, was 
greatest in patients with the poorest prognosis (PD-FLT, 
followed by TSFLT ,9). However, the treatment effect of 
nintedanib was larger in these patients. The insensitivity 
toward chemotherapy observed in the PD-FLT popula-
tion could represent a distinct biology of tumors that are 
potentially more dependent on angiogenesis and in which 
inhibition of angiogenesis might be more effective. Reach-
ing and maintaining a large tumor burden may depend 
heavily on the development of new blood vessels to ensure 
high levels of oxygen and nutrients, rendering them more 
sensitive to the effects of antiangiogenic treatment than 
patients with lower tumor burden. Although nintedanib is 
not approved in squamous patients, we included this patient 
population in our analysis to determine if a meaningful 
treatment effect could be observed in squamous patients. 
Previous meta-analysis has shown that standardized uptake 
value, a semi-quantitative simplified measurement of tissue 
deoxyglucose metabolic rate, has prognostic significance for 
survival in NSCLC.24 Whether differences in standardized 
uptake values may account for the treatment effects observed 
here has not been evaluated, but may be a potential area of 
further investigation.
Decreased tumor burden, slowing increases in tumor 
size, and longer time without new lesions are outcomes that 
provide further evidence of the treatment benefit with ninte-
danib and suggest that further evaluation of the implications 
of these findings for patients with adenocarcinoma is war-
ranted. The current analyses provide a valuable analysis and 
description of the antitumor effect of nintedanib that might 
not be evident from the response rates alone, and as such, 
future trials should consider evaluating tumor dynamics as 
a study endpoint. These analyses confirm that more aggres-
sive tumors obtain the largest benefit from the nintedanib/
docetaxel treatment combination. Another consideration is 
that early assessment of tumor growth kinetics may contribute 
to our understanding of tumor hyperprogression in patients 
undergoing immunotherapy, and as such warrants further 
clinical evaluation. Although what decrease in tumor size 
represents a clinically meaningful improvement for a patient 
has not been established in the literature, measuring change 
in tumor size from a clinical perspective allows for an earlier 
assessment of therapeutic activity and has been correlated 
with survival outcomes.4,6–11
The analyses presented here are exploratory and have 
several limitations. Formal validation of these variables, and 
their potential for use as surrogate endpoints, was beyond 
the scope of this analysis. The study did not systematically 
collect imaging data post-progression on the timing and 
appearance of new lesions beyond PD. It should be noted 
that analyses only included data from selected representative 
lesions based on RECIST that were predefined during the 
trial and may not be representative of all lesions. Individual 
patient heterogeneity should also be considered as some 
SLD data may reflect the size of the primary tumor, while 
other data may reflect the sum of several metastatic lesions 
measured. A further limitation is that our analysis explored 
the PD-FLT and TSFLT ,9 subgroups of adenocarcinoma 
patients, but the same subgroups were not studied in the 
patients with squamous cell carcinoma.
Conclusion
Corresponding well with the OS findings of the LUME-
Lung 1 study, treatment with nintedanib/docetaxel resulted 
in trends toward decreased tumor burden, decelerated tumor 
size over time, and increased time to new occurrences of 
lesions compared with placebo/docetaxel in the overall ade-
nocarcinoma population, with significant benefits observed 
for patients with the poorest prognosis due to aggressive 
tumor dynamics.
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